Evidence map›Paper›PMID 36621992›Full record

ArticleThe Journal of urology2023

Reply by Authors.

Michael T Schweizer, Lawrence True, Roman Gulati, Yibai Zhao, William Ellis, George Schade, Bruce Montgomery, Sonia Goyal, Katie Nega, Alexander K Hakansson and 6 more

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Michael T SchweizerDepartment of Medicine, University of Washington, Seattle, Washington.
Lawrence TrueDepartment of Pathology, University of Washington, Seattle, Washington.
Roman GulatiPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Yibai ZhaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
William EllisDepartment of Urology, University of Washington, Seattle, Washington.
George SchadeDepartment of Urology, University of Washington, Seattle, Washington.
Bruce MontgomeryDepartment of Medicine, University of Washington, Seattle, Washington.
Sonia GoyalDepartment of Medicine, University of Washington, Seattle, Washington.
Katie NegaDepartment of Medicine, University of Washington, Seattle, Washington.
Alexander K HakanssonVeracyte, Inc., San Francisco, California.
Yang LiuVeracyte, Inc., San Francisco, California.
Elai DavicioniVeracyte, Inc., San Francisco, California.
Kenneth PientaThe James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.
Peter S NelsonDepartment of Medicine, University of Washington, Seattle, Washington.
Daniel LinDepartment of Urology, University of Washington, Seattle, Washington.
Jonathan WrightDepartment of Urology, University of Washington, Seattle, Washington.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
Statistical modeling to support population and translational cancer researchR50CA221836 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Roman Gulati · 2017 to 2026
$2.0M
NCI NIH HHS P50 CA097186NCI NIH HHS R50 CA221836
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36621992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.